Utilizing gastric cancer organoids to assess tumor biology and personalize medicine

Miranda Lin, Mei Gao, Michael J Cavnar, Joseph Kim

ORCID number: Miranda Lin (0000-0002-1250-1254); Mei Gao (0000-0001-8960-8749); Michael J Cavnar (0000-0002-6197-7945); Joseph Kim (0000-0001-6313-1516).

Author contributions: All authors contributed equally to conception and design of the study, drafting or making critical revisions to intellectual content in the manuscript, and final approval of the final version of the article.

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: February 23, 2019
Peer-review started: February 23, 2019
First decision: April 15, 2019
Revised: April 25, 2019
Accepted: June 12, 2019
Article in press: June 13, 2019
Published online: July 15, 2019

Miranda Lin, Mei Gao, Michael J Cavnar, Joseph Kim, Department of Surgery, University of Kentucky, Lexington, KY 40536, United States

Corresponding author: Joseph Kim, FACS, MD, Surgical Oncologist, Department of Surgery, University of Kentucky, 800 Rose St., Lexington, KY 40536, United States. joseph.kim@uky.edu

Telephone: +1-859-3238920
Fax: +1-859-3236840

Abstract

While the incidence and mortality of gastric cancer (GC) have declined due to public health programs, it remains the third deadliest cancer worldwide. For patients with early disease, innovative endoscopic and complex surgical techniques have improved survival. However, for patients with advanced disease, there are limited treatment options and survival remains poor. Therefore, there is an urgent need for more effective therapies. Since novel therapies require extensive preclinical testing prior to human trials, it is important to identify methods to expedite this process. Traditional cancer models are restricted by the inability to accurately recapitulate the primary human tumor, exorbitant costs, and the requirement for extended periods of development time. An emerging in vitro model to study human disease is the patient-derived organoid, which is a three-dimensional system created from fresh surgical or biopsy tissues of a patient’s gastric tumor. Organoids are cultured in plastic wells and suspended in a gelatinous matrix, providing a substrate for extension and growth in all dimensions. They are rapid-growing and highly representative of the molecular landscape, histology, and morphology of the various subtypes of GC. Organoids uniquely model tumor initiation and growth, including steps taken by normal stomach cells to transform into invasive, intestinal-type tumor cells. Additionally, they provide ample material for biobanking and screening novel therapies. Lastly, organoids are a promising model for personalized therapy and warrant further investigation in drug sensitivity studies for GC patients.

Key words: Organoids; Gastric cancer; Cancer models; Drug sensitivity; Drug screening; Personalized medicine

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Patient-derived organoids are three-dimensional models of human cancer useful...
for investigating tumor biology and drug discovery. There are now many reports on the utility of organoids in cancer research and personalized therapy. However, none focus on the use of organoid technology in improving outcomes for patients with gastric cancer (GC), which is one of the deadliest cancers worldwide. Our objective is to report the current progress in GC organoid technology in comparison to traditional cancer models and evaluate their potential role in informing personalized clinical decision making for patients with GC.

**Citation:** Lin M, Gao M, Cavnar MJ, Kim J. Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. *World J Gastrointest Oncol* 2019; 11(7): 509-517

**URL:** https://www.wjgnet.com/1948-5204/full/v11/i7/509.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v11.i7.509

## INTRODUCTION

The incidence of gastric cancer (GC) has declined due to global improvements in sanitation, hygiene, and food preservation, and there has been a corresponding decrease in mortality with the implementation of early detection strategies[1-2]. However, GC remains the third leading cause of cancer-related deaths worldwide, with a low 28% 5-year survival rate[1-3]. Although surgical techniques such as D2 lymph node dissection have improved survival for patients with early or localized disease, there is still an urgent need to increase the number of effective therapies available to patients with advanced GC[4].

A variety of cancer models have been developed to bring new therapies to the clinic. The traditional *in vitro* cancer model used to screen novel therapies is the cancer cell line (CCL)[5]. CCLs are rapid-growing cancer models that are derived from a single patient and immortalized[5]. CCLs have the advantage of quick development while producing abundant biological material for testing novel therapies, however due to serial passaging and wide distribution over many generations, they develop extensive chromosomal changes and lose the ability to accurately model the original primary tumor[6]. Additional drawbacks include the two-dimensional nature of this cancer model and lack of structural modeling. Thus, CCLs do not meet the need for a cancer model that represents the molecular profile and three-dimensional architecture of the primary tumor.

After screening of potential new therapies in CCLs, drugs that show the most promise typically undergo testing *in vivo*. Patient-derived tumor xenograft (PDTX) models are the gold standard *in vivo* model, created from either subcutaneous or orthotopic implantation of CCLs or patient tumor tissues into animals[7]. PDTXs are beneficial in that they accurately represent genotypic and phenotypic characteristics of the primary tumor as well as interactions with the microenvironment. However, they are quite costly and require a lengthy amount of time to create, limiting their ability to provide immediate clinically actionable data[7].

Recent studies have demonstrated the potential of using next generation sequencing to predict optimal therapies for individual patients through identification of driver mutations and use of targeted therapies[8]. However, sequencing can be restricted by tumor tissue availability from the patient, cost, time, and the lack of targeted drugs for cancers that do not harbor driver mutations, or when the corresponding targeted drug has not been developed[9]. Thus, there is an important need for an appropriate cancer model that is able to address these limitations and identify the most effective therapy for individual patients with currently available drugs in a timely manner.

Patient-derived organoids are three-dimensional *in vitro* human model systems that recapitulate disease development[10]. The architecture of a typical GI organoid resembles the organ from which it has been derived and maintains its genomic profile[10]. Organoids present an accurate model that provide quicker turnover for experimental procedures and yield results in a shorter period of time than traditional human cancer models. The first gastric organoid culture was developed in 2010 to model the self-renewing and proliferative capacity of Lgr5\textsuperscript{+} stem cells in the gastric pylorus[11]. Since then, organoids have also been successfully created from GC specimens to study oncogenic events and drug sensitivities[12-13]. GC organoids provide the potential to aid development of new therapies and more importantly to test and predict which therapies may work best in GC patients.
In this review, we provide a detailed description of current strides and benefits of GC organoid technology. A brief description of GC organoid culture will be followed by analysis of organoid representation of primary tumor histology, morphology, and heterogeneity, as well as organoid modeling of the subtypes of GC and carcinogenesis. This review will also discuss GC organoids as a vehicle for drug sensitivity testing and biobanking, and finally, describe investigations utilizing GC organoid technology for personalizing therapy and the promise of clinical trials using GC organoids to predict therapies for individual patients.

**ORGANOID CULTURE**

GC organoids can be propagated from surgically resected specimens or biopsies, and various methodologies have been proposed for their successful creation[12-16]. In brief, tumor specimens are washed and centrifuged, and then minced and digested into small pieces (2-5 mm[^2^])[^16]. From our experience, surgical specimens require extensive manual mincing with a scalpel and enzymatic digestion from muscle layers, while biopsies require no enzymatic digestion and only light applied pressure on a microscope slide (Figure 1)[16]. Once the cells are isolated, they are then suspended in matrigel, a basement membrane matrix extracted from Engelbreth-Holm Swarm mouse tumors and containing the extracellular matrix components laminin, type IV collagen, and enactin[^16]. Matrigel provides a gelatinous matrix for organoids to elongate and proliferate three-dimensionally. GC organoids are overlaid with organoid medium, which consists of Advanced Dulbecco’s Modified Eagle’s Medium/F12, Glutamax, HEPES, and penicillin/streptomycin (Figure 2)[19]. Additionally, specific factors important for gastric epithelial cell proliferation and maturation are added to promote growth of organoids, including Wnt3A, R-spondin, Noggin, hEGF, hFGF10, and gastrin (Figure 2)[19]. Once plated in wells and enriched in medium, organoids are incubated at 37 °C and 5% CO[^2^][14].

Initially, GC organoids appear as clumped cells in the three-dimensional matrix. In 3-4 days, they develop into a spherical cystic body surrounded by differentiated cells, including stem cells, mucinous cells, gastric pit cells, and endocrine cells (Figure 3)[16]. If the culture is healthy, GC organoids produce buds and replicate (Figure 4). Once highly confluent, organoids are passaged, i.e., they are digested and resuspended in matrigel into additional wells. Passaging allows cultures to grow and cultivate for many months, producing substantial biological material for testing or freezing for later use[^10,13].

**ACCURATE MODELS OF GC**

*Retention of primary tumor characteristics and representation of tumor morphology*

The current gold standard in vitro model of GC has been the CCL[^11]. However, CCL cultures consist of clones of a single cell that have been distributed and passaged many times, altering chromosomal characteristics to where they no longer represent the original tumor[^1]. In a study of four HeLa cell line cultures, it was found that each culture had a unique genomic profile and activated different pathways in response to a hypoxic environment, demonstrating the effect of different culture conditions and serial passing on the genomic integrity of CCLs[^13]. In contrast, GC organoids retain alterations found in the primary tumor even after serial passaging as evidenced by our own experience showing GC organoids retained copy number alterations after multiple passages[^2^] and a study showing six GC organoids maintained a stable transcriptome even after six months in culture[^14].

Since faithful chromosomal segregation during mitosis requires intact tissue architecture and extracellular cues, CCLs may not represent the degree of chromosomal stability found in the primary tumor from which it was derived[^19]. In contrast, organoids contain a three-dimensional architecture and preserve structural integrity found in the primary tumor. They are composed of multiple cell types and represent the diversity of cell populations found in tumors (Table 1)[21]. They vary morphologically depending on the original tumor’s location in the stomach and tumor histology[^19]. GC organoids derived from intestinal-type tumor specimens resemble typical GI cancer organoids in that they are glandular and form a single lumen lined by a single layer of epithelial cells[^11]. Moderately differentiated intestinal type tumors develop buds, while poorly differentiated intestinal-type tumors form solid clusters[^14]. GC organoids developed from diffuse-type tumor specimens form either loosely cohesive isolated cells or solid cell clusters that do not surround a lumen[^11,19]. Mixed-type tumors develop into organoids containing all morphological
Figure 1 Creation of gastric cancer organoids. Endoscopic biopsy and surgical specimens are obtained from the patient and washed and centrifuged extensively. Endoscopic biopsy specimens are then placed on a microscope slide and pressure is applied by a coverslip onto the tissues to release gastric glands. Surgical specimens are enzymatically digested and minced with a scalpel for gland isolation. Once isolated, glands are suspended in matrigel and plated in drops in pre-warmed wells. Organoids are overlaid with medium.

patterns[13,14].

Representation of histological and molecular subtypes

Recently, therapeutic research efforts have been enhanced by classification systems that delineate molecular features of certain GC subtypes. The classification system proposed by The Cancer Genome Atlas (TCGA) identifies four gastric tumor subtypes: Epstein-Barr Virus-positive (EBV, 9%), those with microsatellite instability (MSI, 22%), genomically stable (20%), and tumors with chromosomal instability (CIN, 50%)[22]. The Lauren classification identifies two histological subtypes of GC based on pathology, epidemiology, and etiology: Intestinal and diffuse type adenocarcinoma. Each GC subtype contains distinct features and biomarkers that may be targeted by specific therapies. Organoids are unique in that they represent the entire genomic landscape and display distinguishable genetic properties depending on the GC subtype outlined by TCGA and Lauren classifications of the primary tumor, making them useful models for drug discovery[22,23]. Chromosomal stability is maintained in MSI and EBV organoids[14]. Diffuse-type organoids encompass both CIN and genomically stable subtypes, while intestinal- and mixed-type organoids display extensive chromosomal instability[13,14]. GC organoids established from a genomically stable tumor contain typical CDH1 gene alterations and organoids established from MSI tumor tissues display characteristic CpG island methylator phenotype and MLH1 hypermethylation[13-23]. Furthermore, EBV organoid lines retain the viral genome as well as characteristic ARID1A and PIK3CA mutations[14]. In one study, a diffuse-type GC organoid line contained the CLDN18-ARHGAP6 fusion gene, which is found in genomically stable tumors. This mutation is not represented in any GC CCLs, further supporting the advantage of organoids to represent all types of GC compared to CCLs[14].

TUMORIGENESIS WITH GC ORGANOIDS

Models of tumor formation, carcinogenesis, and metastasis

The initiation of GC has been studied extensively to target specific genes and molecular events leading to tumor development. Organoids have been used to accurately model this progression. Nanki et al[13] induced diffuse GC-like morphology in normal gastric organoids by knocking out the tumor suppressor CDH1, which plays a role in cell-cell adhesion[12,24]. Further knockout of the oncogene RHOA, a Ras superfamily member, in CDH1-KO organoids resulted in reversion back to normal morphology[12,25]. This suggests malignant phenotype may be induced in normal organoids and organoids can also model reversion back to normal morphology, making them useful for studying initiating events in tumorigenesis. Organoids therefore, may serve as a valuable tool to study phenotypic consequences leading to tumor development after activation or inhibition of specific genes.

Unlike CCLs, organoids have the unique ability to model the development of cancer. Normal gastric organoids and organoids derived from a lesion with intestinal metaplasia from the same patient were not morphologically distinct, but the intestinal metaplasia-derived organoids contained the marker CDX2 while normal organoids did not[13]. Similarly, organoids derived from dysplasia and invasive tumor from the
same patient both expressed representative early GC mutations however, had distinctive chromosomal patterns and unique gene mutations, illustrating the ability of organoids to document the important transition from dysplasia to adenocarcinoma\cite{14}. Altogether, these studies reveal organoids created from pre-malignant lesions are accurate surrogates of the sequence of events leading to cancer, which are not possible with cell lines, and therefore serve as a useful tool for identifying and targeting key mutations of tumor development.

Lastly, organoids created from the same patient’s primary tumor and lymph node metastases show varying degrees of differences, which is believed to model niche-specific changes during metastasis\cite{14}. Thus, the ability of organoids to portray the genotypic and phenotypic events during cancer progression and metastasis provides a unique platform to study important oncological events not accessible through other models.

**DRUG SENSITIVITY TESTING**

**Current limitations of bringing drugs to clinic**

The costs associated with supporting a cancer drug from preclinical development to approval by the United States Food and Drug Administration averages about $719.8 million\cite{26}. The high costs and lengthy amount of time, approximately 5 to 15 years, to bring newly developed drugs into the clinic limit the ability to provide new therapies to patients. One specific delay is the constraint associated with creating PDTX models, which are costly and require 4-8 mo prior to drug testing\cite{7}. From our experience, organoids can be utilized for drug sensitivity testing within two weeks and are less expensive than animal models (Table 1)\cite{12}. While organoids lack the ability to model angiogenesis, they provide ample biological material to rapidly test drugs prior to animal studies.

**Investigation of drug sensitivity testing**

Organoids have the ability to accurately discriminate between different drug treatments. Previously, we created and treated organoids from a patient’s gastric tumor biopsies with the cytotoxic chemotherapies 5-fluorouracil, cisplatin, oxaliplatin, and irinotecan\cite{27}. We observed varying levels of organoid sensitivity to the chemotherapies that correlated with varying IC\textsubscript{50} values. Similarly, Vlachogiannis et al\cite{27} concluded that organoids are useful for modeling patient drug response. An ErbB2-amplified GC organoid line was treated with lapatinib, an antibody that targets the EGFR and HER2 tyrosine kinases that is currently used in combination with capécitabine to treat metastatic breast cancer patients\cite{28}. While the ErbB2-overexpressing GC organoids exhibited strong sensitivity to lapatinib, a GC organoid line with ErbB2 wild-type genotype did not respond. In addition, a GC organoid line with amplified AKT1 was the only organoid line in their cohort to respond significantly to two anti-AKT antibodies, MK-2206 and GSK690693\cite{27}. As such, GC organoids have potential for drug sensitivity screening.

**Creation of GC organoid biobanks for novel drug screening**
Organoid biobanks have been created for various cancer types\textsuperscript{[14,29-32]}. They portray the diverse molecular landscape and corresponding phenotypic characteristics found within a single cancer type and provide abundant biological material for drug sensitivity screening of newly synthesized drugs undergoing preclinical development. In one particular study, 9 GC organoids created from 7 patients were selected for drug screening\textsuperscript{[14]}. Thirty-seven cancer therapies were tested in the organoids, which showed parallel response to that of clinical response with resistance to 5-fluorouracil and cisplatin and sensitivity to oxaliplatin, epirubicin, and paclitaxel. The GC organoids also responded to recently FDA-approved therapies, napabucasin and abemaciclib, and therapies currently undergoing clinical trials, vistusertib and VE-822\textsuperscript{[14]}. These data highlight the potential utility of an organoid biobank to screen novel therapies for efficacy prior to \textit{in vivo} trials, bypassing the additional cost and time constraints associated with screening therapies in mouse models\textsuperscript{[14]}. GC organoid biobanks serve as a useful tool for drug screening by bridging the gap between \textit{ex vivo} and \textit{in vivo} models by accurately portraying the genetic profile of cancers with decreased time and cost constraints.

**PERSONALIZED MEDICINE**

\textit{Limitations of personalized medicine}

Even within GC subtypes, every patient’s tumor is vastly different and therefore, could benefit from a personalized approach. Currently, after biopsy or surgical resection of the primary tumor, a patient’s preserved tumor specimen may be sent for genomic sequencing, such as that offered by Foundation Medicine\textsuperscript{[8]}, to provide information about key driver mutations to guide treatment. While genomic testing provides invaluable biomarker and gene mutation information to help inform certain therapies and clinical trials, there are a few limitations. Optimally, a tumor percentage of 30\% is required per specimen for Foundation Medicine\textsuperscript{[8]} and a minimum threshold of 60\% tumor percentage has historically been required for large next generation sequencing studies\textsuperscript{[22]}. In contrast, organoid establishment is not limited by tumor percentage and furthermore, organoids are created from minimal fresh tissue and expanded in culture, even when tumor tissue is limited\textsuperscript{[27]}. Finally, and perhaps most importantly, next generation sequencing testing has been criticized for lack of benefit to the majority of patients who have somatic alterations in their cancers that have no corresponding targeted therapies available in the clinic\textsuperscript{[9]}. These patients may benefit from functional assays using organoids to test a variety of drugs to determine the best available treatment.

\textit{Yielding drug treatment results in a clinically actionable time period}

GC organoids established directly from patients may be used to test standard of care cytotoxic and targeted drug regimens, providing great potential for personalized medicine. However, GC organoids are mostly created from surgically resected tumor specimens. Surgery provides abundant tissue and serves as a good source for creating organoid biobanks for drug discovery and signaling studies. However, creating organoids from surgical specimens does not benefit the patient undergoing neoadjuvant therapies. Additionally, many patients with GC have metastatic disease and are not candidates to undergo surgery. Therefore, in order to personalize medicine for individual patients, a new avenue for organoid creation must be
explored. We recently published a novel technique for successfully establishing GC organoids from esophagogastroduodenoscopy (EGD) (Figure 1).[12] Many patients suspected to have GC will undergo EGD for diagnosis and staging. Therefore, creating organoids from EGD biopsies for drug sensitivity testing may directly yield clinically relevant results for patients who are ineligible for surgical intervention. Our technique has yielded abundant EGD derived organoids for testing multiple standard of care drug regimens and combination therapies within two weeks of organoid establishment (unpublished data), providing a valuable model for clinical prediction of the best therapies for individual patients. Furthermore, since almost every patient suspected of GC will undergo EGD, creating organoids from biopsies may serve as an additional source of abundant human biological material for biobanking.

Clinical trials using GC organoids to personalize therapy
With the ability to quickly develop large numbers of organoids that accurately portray an individual patient’s tumor, GC organoids show high clinical utility for predicting drug sensitivities in patients. This unique advantage is currently being assessed in a human clinical trial where GC organoids created from patients with resectable cancer will be treated with the same neoadjuvant systemic therapy received by the patient, and in vitro cytotoxicity will be correlated to in vivo response (OPPOSITE trial: NCT03429816).[34] The future of personalized medicine in GC includes human trials implementing GC organoids to test various drugs and predict the best treatment for individual patients with advanced GC.

CONCLUSION
Organoid technology has provided the ability to model GC with more accuracy than traditional in vitro models. They retain GC biomarkers and display varying morphology depending on the histology and molecular subtype of the primary tumor from which they are derived. GC organoids are unique in that they recapitulate important molecular events leading to carcinogenesis and metastasis unlike CCLS. They are less costly and less time-consuming to create than in vivo PDTX models, making them an appropriate vehicle for biobanking and comprehensive drug screening. While GC organoids present a unique, in vitro model, there are a few limitations. Unlike PDTX models, organoids are unable to mimic the in vivo tumor microenvironment in that they lack blood vessels for studying cancer angiogenesis and metastasis. In addition, they are grown in optimal conditions and growth-promoting media. Despite these restrictions, GC organoids overcome current limitations in precision medicine that require minimum tumor percentage and yet, organoids provide a more relevant predictor of drug response than next generation sequencing methods. With the ability to create GC organoids from diagnostic biopsy procedures, multiple drug regimens can be tested at once to yield actionable results in a clinically relevant time interval, providing avenues for personalized medicine for GC patients.
| Model system | In vitro | Cells in microenvironment | In vitro |
|-------------|---------|--------------------------|---------|
| Shape | 2D | Medium | 3D |
| Time prior to drug testing | 1-2 d | Scarce | 10-14 d |
| Cellularity | Clones of single cell | Abundant | Multiple cell types |
| Biological material produced | Abundant | Scarce | Abundant |
| Cost | Low | High | Medium |
| Tumor architecture | None | Represented | Represented |
| Primary tumor represented | No | Yes | Yes |

**REFERENCES**

1. Balakrishnan M, George R, Sharma A, Graham DY. Changing Trends in Stomach Cancer Throughout the World. *Curr Gastroenterol Rep* 2017; 19: 36 [PMID: 28750504 DOI: 10.1007/s11894-017-0575-8]

2. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. *Int J Cancer* 2013; 132: 1272-1276 [PMID: 23886688 DOI: 10.1002/ijc.27965]

3. Marquès-Lespier JM, González-Pons M, Cruz-Corrales M. Current Perspectives on Gastric Cancer. *Gastroenterol Clin North Am* 2016; 45: 413-428 [PMID: 27546840 DOI: 10.1016/j.gcna.2016.04.002]

4. Songun I, Patter H, Kronenbourg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010; 11: 439-449 [PMID: 2049751 DOI: 10.1016/S1470-2045(10)70070-X]

5. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. *J Natl Cancer Inst* 2013; 105: 452-458 [PMID: 23434001 DOI: 10.1093/jnci/djt007]

6. Nelson-Rees WA, Owens RB, Armstrong P, Kniazeff AJ. Source, alterations, characteristics and use of a new dog cell line (CI276). *In Vitro* 1976; 12: 665-669 [PMID: 991063 DOI: 10.1016/S0020-2752(79)74686-8]

7. Hidalgo M, Amant F, Blankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong J, Jonkers J, Madlansamo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov* 2014; 4: 998-1013 [PMID: 25185190 DOI: 10.1158/2159-8290.CD-14-0001]

8. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwamin K, Maillet A, Bauli J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Maloney K, Zvirko Z, Donahue A, Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechman E, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol* 2013; 31: 1023-1031 [PMID: 24142049 DOI: 10.1038/nbt.2696]

9. Letal A. Functional precision cancer medicine-moving beyond pure genomics. *Nat Med* 2017; 23: 1028-1035 [PMID: 28886003 DOI: 10.1038/nm.4389]

10. Merker SR, Weitz J, Stange DE. Gastrointestinal organoids: How they gut it out. *Dev Biol* 2016; 420: 239-250 [PMID: 27521455 DOI: 10.1016/j.ydbio.2016.08.010]

11. Barker N, Huang M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, van den Born M, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechman E, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol* 2013; 31: 1023-1031 [PMID: 24142049 DOI: 10.1038/nbt.2696]

12. Gao M, Lin M, Rao M, Thompson H, Hirai K, Choi M, Georgakis GV, Sasson AR, Bucobo JC, Tizman D, D’Souza LS, Buscaglia JM, Davis J, Shroyer KR, Li J, Powers S, Kim J. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. *Ann Surg Oncol* 2018; 25: 2767-2775 [PMID: 30003451 DOI: 10.1245/s10434-018-6662-2]

13. Nanki K, Toshimitsu A, Takano F, Fujii M, Shimokawa M, Ohta Y, Matano M, Seino T, Nishikori S, Ishikawa K, Kawasaki K, Togasaki K, Takahashi S, Sukawa Y, Ishida H, Sugimoto S, Kawakubo H, Kim J, Kitagawa Y, Sekine S, Koo BK, Kanai T, Sato T. Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis. *Cell* 2018; 174: 856-869.e17 [PMID: 30096312 DOI: 10.1016/j.cell.2018.07.027]

14. Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, Chan D, Chan AS, Ma S, Lam KO, Bartfeld S, Man AHEY, Lee BCH, Chan ASY, Wong JWH, Cheng PSW, Chan AKW, Zhang J, Shi J, Fan X, Kwong DLW, Mak TW, Yuen ST, Clevers H, Leung SY. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. *Cell Stem Cell* 2018; 23: 882-897.e11 [PMID: 30344100 DOI: 10.1016/j.stem.2018.09.016]

15. Seltitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Groll M, Suhring L, Schweitzer C, Scholich S, Uhlenmann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Auer DE, Klink B, Weitz J, Stange DE. Human gastric cancer modelling using organoids. *Gut* 2019; 68: 207-217 [PMID: 29703791 DOI: 10.1136/gutjnl-2017-315449]

16. Bartfeld S, Clevers H. Organoids as Model for Infectious Diseases: Culture of Human and Murine Stomach Organoids and Microinjection of Helicobacter Pylori. *J Vis Exp* 2015 [PMID: 26650279 DOI: 10.3791/53359]

17. Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. *Proteomics* 2010; 10: 1886-1890 [PMID: 20162561 DOI: 10.1002/pmic.200900758]

18. Sato T, Clevers H. SnapShot: Growing Organoids from Stem Cells. *Cell* 2015; 161: 1700-1700.e1 [PMID: 26691044 DOI: 10.1016/j.cell.2015.06.028]

19. Frattini A, Fabbrini M, Vali R, De Paoli E, Montalbano G, Gribaldo L, Pasquali F, Maserati E. High...
variability of genomic instability and gene expression profiling in different HeLa clones. Sci Rep 2015; 5: 15377 [PMID: 26483214 DOI: 10.1038/srep15377]

20 Knouse KA, Lopez KE, Bachofner M, Amon A. Chromosome Segregation Fidelity in Epithelia Requires Tissue Architecture. Cell 2018; 175: 200-211.e13 [PMID: 30146160 DOI: 10.1016/j.cell.2018.07.042]

21 Bartfeld S, Clevers H. Stem cell-derived organoids and their application for medical research and patient treatment. J Mol Med (Berl) 2017; 95: 729-735 [PMID: 28391362 DOI: 10.1007/s00109-017-1531-7]

22 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

23 Lauren P. The two histological main types of gastric carcinoma: diffuse type and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675 DOI: 10.1111/apm.1965.64.1.31]

24 Funakoshi T, Miyamoto S, Kakiuchi N, Nikaido M, Setoyama T, Yokoyama A, Horimatsu T, Yamada A, Torishima M, Kosugi S, Yamada H, Sugimura H, Haga H, Sakai Y, Ogawa S, Seno H, Muto M, Chiba T. Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer. Gastric Cancer 2018 [PMID: 30542785 DOI: 10.1007/s10120-018-00912-w]

25 Aspenström P. Activated Rho GTPases in Cancer-The Beginning of a New Paradigm. Int J Mol Sci 2018; 19: pii: E3849 [PMID: 30544928 DOI: 10.3390/ijms19123849]

26 Prasad V, Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med 2017; 177: 1569-1575 [PMID: 28892524 DOI: 10.1001/jamainternmed.2017.3601]

27 Vlachogiannis G, Hedayat S, Vatsiou A, Jannin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford J, Burke B, Rata M, Koh DM, Tunaruu N, Collins D, Hulki-Wilson S, Raguhan C, Spiteri I, Moorcroft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 2018; 359: 920-926 [PMID: 29872484 DOI: 10.1126/science.aao2774]

28 Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30: 1426-1447 [PMID: 18803986 DOI: 10.1016/j.clinthera.2008.08.008]

29 Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Shoner A, Sailer V, Angello M, Puca L, Rosati R, McNary TJ, Charukova Y, Cheung C, Triscott J, Pesapia D, Rao R, Mosquera JM, Robinson B, Feltas BM, Emde C, Wieden HE, Gadi VK, Bariapin B, EI, Gennari C, Cantley LC, Rubin MA. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov 2017; 7: 462-477 [PMID: 28331002 DOI: 10.1158/2159-8290.CD-16-1154]

30 van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Hoult W, van Gomp J, Taylor-Weiner A, Kester L, Versteeg R, van Oudenaarden A, Saez-Rodriguez J, Vries RG, Getz G, Wessels L, Stratton MR, McDermott U, Meyerson M, Garnett MJ, Clevers H. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161: 933-945 [PMID: 25957691 DOI: 10.1016/j.cell.2015.03.053]

31 Lee SH, Hu W, Matulay JT, Silva MV, Ozcerek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, Bergren SK, Pietzak EJ, Anderson CB, Benson MC, Coleman JA, Taylor BS, Abate-Shen C, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, van Sluis LC, Rubin MA. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov 2017; 7: 462-477 [PMID: 28331002 DOI: 10.1158/2159-8290.CD-16-1154]

32 van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Hoult W, van Gomp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, van Sluis LC, Rubin MA. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov 2017; 7: 462-477 [PMID: 28331002 DOI: 10.1158/2159-8290.CD-16-1154]

33 Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004; 40: 827-836 [PMID: 15120038 DOI: 10.1016/j.ejca.2003.11.028]

34 Haag GM. OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophageal Gastric Carcinoma (OPPOSITE). [accessed 2019 Feb 18]. In: clinicaltrials.gov [Internet]. Heidelberg, Germany. Available from: URL: https://clinicaltrials.gov/ct2/show/NCT03429816?term=NCT03429816ClinicalTrials.gov Identifier: NCT03429816
